IRIS UniCatt

Borghetti, Alberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.825
EU - Europa 4.066
AS - Asia 3.558
SA - Sud America 738
AF - Africa 126
OC - Oceania 30
Continente sconosciuto - Info sul continente non disponibili 6
AN - Antartide 1
Totale 13.350
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.628
SG - Singapore 1.619
IT - Italia 879
DE - Germania 762
CN - Cina 699
BR - Brasile 612
SE - Svezia 527
FR - Francia 442
NL - Olanda 379
VN - Vietnam 337
PL - Polonia 255
GB - Regno Unito 221
IE - Irlanda 153
IN - India 138
FI - Finlandia 125
BD - Bangladesh 115
CA - Canada 112
ID - Indonesia 102
JP - Giappone 102
HK - Hong Kong 83
UA - Ucraina 66
RU - Federazione Russa 62
AR - Argentina 48
TR - Turchia 47
MX - Messico 43
PK - Pakistan 41
IQ - Iraq 35
KR - Corea 34
AT - Austria 33
BE - Belgio 32
ES - Italia 32
ZA - Sudafrica 31
SA - Arabia Saudita 29
IR - Iran 28
AU - Australia 27
PH - Filippine 20
VE - Venezuela 20
LT - Lituania 19
MA - Marocco 18
CI - Costa d'Avorio 17
EG - Egitto 16
CH - Svizzera 14
MY - Malesia 14
EC - Ecuador 13
CO - Colombia 11
KE - Kenya 11
PY - Paraguay 11
UZ - Uzbekistan 11
CL - Cile 10
CZ - Repubblica Ceca 10
IL - Israele 10
JM - Giamaica 10
NP - Nepal 10
AE - Emirati Arabi Uniti 9
TN - Tunisia 9
TW - Taiwan 8
AZ - Azerbaigian 7
JO - Giordania 7
MD - Moldavia 7
NG - Nigeria 7
AL - Albania 6
BO - Bolivia 6
GR - Grecia 6
TH - Thailandia 6
KG - Kirghizistan 5
KZ - Kazakistan 5
LB - Libano 5
OM - Oman 5
PA - Panama 5
PE - Perù 5
PT - Portogallo 5
TT - Trinidad e Tobago 5
BH - Bahrain 4
CR - Costa Rica 4
DK - Danimarca 4
DO - Repubblica Dominicana 4
EU - Europa 4
RO - Romania 4
BY - Bielorussia 3
ET - Etiopia 3
HR - Croazia 3
MM - Myanmar 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
PR - Porto Rico 3
PS - Palestinian Territory 3
QA - Qatar 3
RS - Serbia 3
SD - Sudan 3
BG - Bulgaria 2
BN - Brunei Darussalam 2
CM - Camerun 2
DZ - Algeria 2
GE - Georgia 2
GT - Guatemala 2
HN - Honduras 2
KW - Kuwait 2
LK - Sri Lanka 2
LU - Lussemburgo 2
MG - Madagascar 2
Totale 13.320
Salva come PNG Salva come JPEG
Città #
Singapore 908
Chandler 626
Ashburn 517
San Jose 454
Amsterdam 360
New York 216
Kraków 209
Milan 195
Rome 186
Dublin 150
Beijing 148
Los Angeles 137
Dallas 116
Ho Chi Minh City 115
The Dalles 107
Lauterbourg 97
Tokyo 97
Jakarta 93
Hefei 89
Hanoi 88
St Louis 85
San Mateo 79
Helsinki 72
Frankfurt am Main 69
Hong Kong 69
Chicago 68
Boston 67
Jacksonville 62
São Paulo 61
Munich 52
Ann Arbor 48
Princeton 48
Wilmington 48
Marseille 43
Council Bluffs 41
Santa Clara 41
London 38
Orem 37
Tukwila 37
Boardman 36
Houston 36
Warsaw 35
Buffalo 34
Montreal 34
Redmond 33
Nanjing 32
Brooklyn 31
Moscow 30
Brussels 29
Nuremberg 29
Denver 28
Lancaster 27
Seoul 27
Cattolica 26
Paris 26
Kent 25
Toronto 25
Atlanta 24
Düsseldorf 24
Vienna 23
Pune 21
Rio de Janeiro 21
Seattle 21
Chennai 20
Dearborn 20
Manchester 20
Fairfield 19
Haiphong 19
Turku 19
Poplar 18
Roubaix 18
Stockholm 18
Johannesburg 17
Lawrence 17
North Bergen 17
Phoenix 17
Abidjan 16
Woodbridge 16
Augusta 15
Lahore 15
Lappeenranta 15
Mexico City 15
Portsmouth 15
Belo Horizonte 14
Bremen 14
Dhaka 14
Dammam 13
Redwood City 13
Tianjin 13
Da Nang 12
Guangzhou 12
Naples 12
Norwalk 12
Washington 12
Izmir 11
Kish 11
Nürnberg 11
Shanghai 11
Bexley 10
Hangzhou 10
Totale 7.201
Salva come PNG Salva come JPEG
Nome #
Functional associations between polymorphic regions of the human 3'IgH locus and COVID-19 disease 805
Post-COVID-19 global health strategies: the need for an interdisciplinary approach 529
Asthma in patients admitted to emergency department for COVID-19: prevalence and risk of hospitalization 329
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 238
Post-COVID-19 global health strategies: the need for an interdisciplinary approach 231
Prevalence of osteoporosis and predictors of low BMD in a cohort of HIV-1-infected patients in Rome: features of a population at high risk 219
Liver fibrosis is associated with cognitive impairment in HIV-positive patients 219
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 218
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 214
Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE) 210
Retinal capillary involvement in early post-COVID-19 patients: a healthy controlled study 202
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 199
Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients 197
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 197
Residual respiratory impairment after COVID-19 pneumonia 196
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 188
Cardiovascular Disease Risk in a Cohort of Virologically Suppressed People Living with HIV Switching to Doravirine: Preliminary Data from the Real Life 177
Residual respiratory impairment after COVID-19 pneumonia 177
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 173
Treatment of Aorto-iliac and Infrainguinal Vascular Infections with a Prefabricated Bovine Pericardial Graft 172
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 171
Shall we dance? Extending tango's results to clinical practice 168
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 166
Psychological Distress After Covid-19 Recovery: Reciprocal Effects With Temperament and Emotional Dysregulation. An Exploratory Study of Patients Over 60 Years of Age Assessed in a Post-acute Care Service 165
Lung ultrasonography for early management of patients with respiratory symptoms during COVID-19 pandemic 161
The University of California San Diego performance-based skills assessment: a useful tool to detect mild everyday functioning difficulties in HIV-infected patients with very good immunological condition 160
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients 159
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 157
Are we ready for long-acting? A feasibility evaluation of long-acting cabotegravir–rilpivirine in clinical practice 152
Difference in the neurocognitive functions of WLWH and MLWH in an Italian cohort of people living with HIV 151
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study 149
HIV-Related Internalized Stigma and Patient Health Engagement Model in an Italian Cohort of People Living With HIV 148
Comparing the long-term effectiveness and safety of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate as first-line regimens: A real life multicentre cohort 144
Psychological distress during the initial stage of the COVID-19 pandemic in an italian population living with HIV: An online survey 139
The University of California San Diego performance-based skills assessment: a useful tool to detect mild everyday functioning difficulties in HIV-infected patients with very good immunological condition 137
Impact of the COVID-19 Pandemic on Health Care Is Negatively Associated With Psychosocial Well-Being in an Italian Cohort of People Living With HIV 133
Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line 130
Seroprevalence of sars-cov-2 antibodies in hiv-infected patients in rome, italy during the covid-19 outbreak 127
HIV and vicarious stigma in a cohort of people living with HIV in Italy: What happens when the stigma is fueled by healthcare providers? 126
Short Communication: Comparing Lamivudine+Dolutegravir and Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategies: Preliminary Results from Clinical Practice 123
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 120
SARS-CoV-2 infection in a highly experienced person living with HIV 120
Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort 119
Prevalence, incidence and predictors of anal high-risk HPV infections and cytological abnormalities in HIV-infected individuals 118
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients 118
Early use of tecovirimat in a young man with severe mpox skin lesions: a case report 117
Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study 117
Comparative safety review of recommended, first-line single-tablet regimens in patients with HIV 117
Use of Long-Acting Therapies for HIV Care in Italy: Are People Living with HIV Prepared for Change? A Cross-Sectional Study 117
Differences in the Long-term Impact of the COVID-19 Pandemic on the Mental Health and Professional Quality of Life of Resident and Specialist Physicians 116
The association between stigma and wellbeing in an Italian cohort of PLWH: The role of social support and personal factors 115
Blood telomere length gain in people living with HIV switching to dolutegravir plus lamivudine versus continuing triple regimen: a longitudinal, prospective, matched, controlled study 115
Use of telehealth for HIV care in Italy: Are doctors and patients on the same page? A cross-sectional study 115
Changes in Metabolic Profile in PLWHIV Switching to Doravirine-Based Regimen 114
Efficacy of Lamivudine Plus Dolutegravir vs Dolutegravir-Based 3-Drug Regimens in People With HIV Who Are Virologically Suppressed 113
Atypical ductal hyperplasia on vacuum-assisted breast biopsy: a scoring system to predict the risk of upgrade to malignancy 113
Derivation and validation of a scoring system to assess pre-test probability of being COVID-19 positive 112
Risk of Tumor Onset in HIV+ Patients on Two-Drug Regimens: A Cohort Study in an Italian Hospital 111
Letter to the Editor: Real-Life Experience of Long-Acting Cabotegravir-Rilpivirine Combination in a Person Living with HIV with Detectable Viremia: A Case Report 108
Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy 107
Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy 106
The need to continue testing for HIV, even during the coronavirus disease 2019 (COVID-19) pandemic 103
Clinical presentation of human monkeypox virus infection during the 2022 outbreak: descriptive case series from a large italian Research Hospital 103
People Living with HIV in the COVID-19 Era: A Case Report 102
Virological outcomes with dolutegravir plus either lamivudine or two NRTIs as switch strategies: a multi-cohort study 101
Implementing a Personalized Antimicrobial Stewardship Program for Women with Gynecological Cancers and Healthcare-Associated Infections 100
Dolutegravir Discontinuation for Neuropsychiatric Symptoms in People Living with HIV and Their Outcomes after Treatment Change: A Pharmacogenetic Study 99
Characteristics of mental health interventions in a cohort of Italian PLWH over the last five years: impact of HIV disease and outbreak of COVID-19 pandemic 99
Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients 98
New insight of human-IgH 3′regulatory regions in immunoglobulins switch 97
Determinants of SARS-COV-2 seroconversion in a cohort of recovered patients 97
COVID-19 diagnosis does not rule out other concomitant diseases 97
Real World Data from an Italian Outpatient Clinical Setting and from Home Care Assistance of Treatment-Experienced PWH Switching to CAB + RPV Regimen: A Prospective Observational Study 96
Nasopharingeal bacterial and fungal colonization in HIV-positive versus HIV-negative adults 96
Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting 95
Off-label use of tocilizumab in patients with SARS-CoV-2 infection 95
No evidence of SARS-CoV-2 circulation in HIV-infected patients between December 2019 and February 2020 in Rome, Italy 94
Derivation and validation of a scoring system to assess pre-test probability of being COVID-19 positive 93
Transmitted drug resistance to NRTIs and risk of virological failure in naïve patients treated with integrase inhibitors 92
People Living with HIV in the COVID-19 Era: A Case Report 90
Assessing dengue seroprevalence among people living with HIV (PLWH) in rome, Italy: Insights from the 2023 Italian autochthonous outbreak 85
Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients during Lamivudine plus Dolutegravir Maintenance Therapy in Clinical Practice 84
Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: A multicenter retrospective cohort study from 2007 to 2015 84
Short Communication: Efficacy and Safety of Dolutegravir plus Lamivudine as a First-Line Regimen in Clinical Practice 82
Focal status epilepticus as unique clinical feature of COVID-19: A case report 81
Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study 81
Still much to learn about the diagnostic role of SARS-CoV-2 antibody detection 79
Real-life findings on the impact of the COVID-19 pandemic on HIV care 78
Lung ultrasonography for early management of patients with respiratory symptoms during COVID-19 pandemic 77
Kaposi-like manifestations in a newly diagnosed aids transgendered patient with silicone embolism syndrome and disseminated tuberculosis 76
Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV 74
No significant changes in body fat mass in virologically suppressed, HIV-positive patients switched to lamivudine-Dolutegravir 73
The need to continue testing for HIV, even during the coronavirus disease 2019 (COVID-19) pandemic 70
Evolution of cellular HIV DNA levels in virologically suppressed patients switching to dolutegravir/lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study 66
Comparison of HIV-DNA decay in naive patients starting dolutegravir plus lamivudine or dolutegravir-based triple therapy 63
Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients 60
Are we really ready for dual therapy in naive people with HIV? The experience from a large university hospital in Rome, Italy 5
‘Leaving no stones unturned’: up to 10 years results on the effectiveness, tolerability and metabolic safety of dolutegravir+lamivudine (DTG+3TC) as a switch regimen in the ODOACRE cohort 1
Totale 13.530
Salva come PNG Salva come JPEG
Categoria #
all - tutte 56.431
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.431
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022714 35 21 16 74 20 23 65 116 31 56 89 168
2022/20232.059 212 261 180 330 209 273 85 156 220 54 60 19
2023/20241.121 43 227 36 100 62 183 77 30 39 54 136 134
2024/20252.263 29 54 262 87 176 93 147 115 300 187 469 344
2025/20266.077 733 175 353 712 988 931 821 267 304 421 206 166
2026/202796 96 0 0 0 0 0 0 0 0 0 0 0
Totale 13.530